EGFR and non-small cell lung carcinoma: A study involving 233 NSCLC patients with EGFR mutation reported that the acquired resistance rate of T790M mutation was not different between EGFR‐TKI types (42.9% of gefitinib users, 45.7% of erlotinib users, and 45.3% of afatinib users).24